Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced earnings of $3.62, delivering a surprise of +36300%.Over the last four quarters, the compa ...